Discover
FBRX
Forte Biosciences, Inc.
76.99
42 x 76.99
2 x 98.52
bid
ask
+
0.00
0.00%
04:00 PM
timesize
| Ytd | 182.32% | |
| 1y | 583.75% |
76.96
day range
77.00
10.11
52 week range
77.20
| Open | 76.97 | Prev Close | 76.99 | Low | 76.96 | High | 77.00 | Mkt Cap | 1.63B |
| Vol | 1.40M | Avg Vol | 1.34M | EPS | -4.57 | P/E | N/A | Forward P/E | -18.89 |
| Beta | 2.62 | Short Ratio | 0.82 | Inst. Own | 96.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 55.18 | 200-d Avg | 33.25 | 1yr Est | 73.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-13 | 2026-09 | -0.9 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -1.08 | -0.97 | 0.11 | 10.19% |
| 2026-05-21 | 2026-03 | -1.16 | -1.24 | -0.08 | -6.90% |
| 2026-03-31 | 2025-12 | -1.42 | -1.45 | -0.03 | -2.11% |
| 2025-11-14 | 2025-09 | -1.04 | -0.99 | 0.05 | 4.81% |
| 2025-08-14 | 2025-06 | -1.21 | -0.96 | 0.25 | 20.66% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-28 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2026-07-21 | Barclays | Upgrade | Overweight | |
| 2025-11-25 | Evercore ISI Group | Upgrade | Outperform | |
| 2025-11-17 | Chardan Capital | Upgrade | Buy | Buy |
| 2025-08-18 | Guggenheim | Upgrade | Buy | |
| 2025-08-15 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-30 | RILEY ANTONY A | Chief Financial Officer | 42.60K | Conversion of Exercise of derivative security |
| 2026-06-30 | WAGNER PAUL A | Chief Executive Officer | 85.48K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Federated Hermes, Inc. | 2.11M | 162.49M | 9.94% |
| 2026-06-29 | Orbimed Advisors LLC. | 1.58M | 121.47M | 7.43% |
| 2026-06-29 | Fred Alger Management, LLC | 1.44M | 110.84M | 6.78% |
| 2026-06-29 | Jupiter Topco LLC | 1.37M | 105.71M | 6.47% |
| 2026-06-29 | Blackrock Inc. | 1.22M | 94.15M | 5.76% |
| 2026-06-29 | Affinity Asset Advisors, Llc | 1.15M | 88.18M | 5.40% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 1.25M | 96.35M | 5.90% |
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 832.10K | 64.06M | 3.92% |
| 2026-06-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 502.79K | 38.71M | 2.37% |
| 2026-04-29 | ALGER FUNDS-Alger Small Cap Focus Fund | 496.06K | 38.19M | 2.34% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 457.92K | 35.25M | 2.16% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 393.73K | 30.31M | 1.85% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2024-08-28 |
| 1 : 15 | 2020-06-16 |